Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m
August 5, 2014
PDF 223.8 KB
DownloadRNA medicines for the 21st century.
Forbion Capital Partners supported Santaris Pharma since 2006 leading its Series B financing round and in all subsequent rounds.
Santaris Pharma was acquired by Roche in August 2014 for up to $450 million.
Human Health
Industry
Biotech
Status
Realised
Location
Denmark